Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Corrie, P G [et al]
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
RightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology
MetadataShow full item record
Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor (VEGF) shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurrence.